GDRX insider activity: RSU vesting and small share disposals disclosed
Rhea-AI Filing Summary
GoodRx Holdings insider activity: The company's Chief Accounting Officer reported multiple transactions in Class A common stock and related restricted stock units. The filing shows acquisitions through vesting of 12,433 restricted stock units (10,201 and 2,232) convertible one-for-one into Class A shares, and dispositions of 4,449 shares sold across two trades at $4.00 per share. After these transactions the reporting person beneficially owned 145,276 to 147,493 Class A shares across reported lines, and held a total of 40,803 and 22,323 underlying shares from the respective RSU awards following the reported vesting events. The RSU awards vest initially at 6.25% with the remainder scheduled to vest in approximately equal quarterly installments over 15 quarters. The transactions reflect routine insider vesting and partial sale activity of equity compensation.
Positive
- RSU vesting increased insider alignment with 12,433 restricted stock units converting one-for-one into shares
- Clear vesting schedule disclosed: 6.25% initial tranche then equal quarterly installments over 15 quarters, providing predictability
Negative
- Insider sold 4,449 shares in two transactions at $4.00 per share, modestly increasing public float
- Multiple discrete transactions could incrementally dilute near-term insider ownership as vested RSUs convert into shares
Insights
TL;DR: Routine insider vesting with modest sales; not clearly material to valuation.
The reported activity shows vesting-driven acquisition of restricted stock units and small open-market disposals at $4.00 per share. The transactions appear to be execution of equity compensation vesting schedules rather than opportunistic large-scale selling. The net effect modestly alters insider holdings but does not indicate a change in corporate control or a material capital-raising event. Investors should note the vesting cadence: an initial 6.25% tranche then equal quarterly installments across 15 quarters, which implies predictable future share release into the float.
TL;DR: Governance signal is neutral; transactions align with grant terms and standard vesting.
The filing documents vesting-triggered issuances of RSUs and subsequent small disposals. The disclosure includes specific plan mechanics: one share per RSU and a structured vesting schedule. The presence of partial sales at a fixed price suggests routine liquidity management by the reporting person. There are no indications of accelerations, amendments, or unusual derivative activity. From a governance perspective this is consistent with standard executive compensation realization.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 10,201 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 2,232 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 10,201 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Class A Common Stock | 3,650 | $4.00 | $15K |
| Exercise | Class A Common Stock | 2,232 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Class A Common Stock | 799 | $4.00 | $3K |
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
- F2. The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.
- F3. The restricted stock unit award will vest as to 6.25% of the underlying shares on June 8, 2024 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.
FAQ
What transactions did the GoodRx (GDRX) reporting person report?
What is the vesting schedule for the RSU awards?
Were any derivative securities involved in the report?
AI-generated analysis. How Rhea-AI works. Not financial advice.